HC
CPRX

Hurley Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Hurley Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31 Hold
1
– – ﹤0.01% 667
2026
Q1 		$25 Hold
1
– – ﹤0.01% 659
2025
Q4 		$23 Hold
1
– – ﹤0.01% 587
2025
Q3 		$20 Hold
1
– – ﹤0.01% 686
2025
Q2 		$22 Hold
1
– – ﹤0.01% 461
2025
Q1 		$24 Hold
1
– – ﹤0.01% 497
2024
Q4 		$21 Buy
+1
New +$21 ﹤0.01% 402

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hurley Capital's CPRX Position: Q2 2026 in Review

Hurley Capital held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 1 share worth $31. The position accounts for ﹤0.01% of the portfolio, ranked #667.

Hurley Capital first reported a position in CPRX in Q4 2024 and has held it in 7 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Hurley Capital held 1 share of Catalyst Pharmaceutical worth $31 as of Q2 2026.
  • Hurley Capital left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #667 holding.
  • Hurley Capital first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.